BerGenBio
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Manufacturing
Description
BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2019-11-07 06:00 |
BERGENBIO ASA: Invitation to third quarter 2019 results presentation and webcast
|
Norwegian | 210.4 KB | ||
| 2019-11-07 06:00 |
BERGENBIO ASA: Invitation to third quarter 2019 results presentation and webcast
|
English | 2.7 KB | ||
| 2019-11-06 06:00 |
BERGENBIO'S BEMCENTINIB MEETS PRIMARY ENDPOINT IN FIRST COHORT OF PHASE 2 NSCLC…
|
English | 257.2 KB | ||
| 2019-11-06 06:00 |
BERGENBIO'S BEMCENTINIB MEETS PRIMARY ENDPOINT IN FIRST COHORT OF PHASE 2 NSCLC…
|
English | 7.0 KB | ||
| 2019-10-22 12:23 |
BerGenBio Receives FDA Approval of Fast Track Designation for Bemcentinib
|
English | 95.1 KB | ||
| 2019-10-22 12:23 |
BerGenBio Receives FDA Approval of Fast Track Designation for Bemcentinib
|
English | 6.8 KB | ||
| 2019-10-02 05:00 |
BerGenBio to Present clinical data from Phase II trial with selective AXL inhib…
|
English | 219.7 KB | ||
| 2019-10-02 05:00 |
BerGenBio to Present clinical data from Phase II trial with selective AXL inhib…
|
English | 4.2 KB | ||
| 2019-09-27 10:05 |
BerGenBio Presents Phase II Trial Updates with Selective AXL Inhibitor Bemcenti…
|
English | 109.7 KB | ||
| 2019-09-27 10:05 |
BerGenBio Presents Phase II Trial Updates with Selective AXL Inhibitor Bemcenti…
|
English | 7.0 KB | ||
| 2019-09-10 11:13 |
BerGenBio to Present at H.C. Wainwright 21st Annual Global Life Sciences Confer…
|
English | 3.1 KB | ||
| 2019-09-08 05:00 |
BerGenBio Presents Phase II Trial Updates with Selective AXL Inhibitor Bemcenti…
|
English | 7.4 KB | ||
| 2019-09-03 09:01 |
BerGenBio ASA: Share capital increase
|
English | 1.8 KB | ||
| 2019-09-02 15:00 |
BerGenBio ASA: Primary insider notification
|
English | 2.9 KB | ||
| 2019-08-28 14:30 |
BerGenBio ASA: Increase of share capital, exercise of share options and primary…
|
English | 4.8 KB |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
